1. Home
  2. PBYI vs GLDG Comparison

PBYI vs GLDG Comparison

Compare PBYI & GLDG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBYI
  • GLDG
  • Stock Information
  • Founded
  • PBYI 2010
  • GLDG 2009
  • Country
  • PBYI United States
  • GLDG Canada
  • Employees
  • PBYI N/A
  • GLDG N/A
  • Industry
  • PBYI Biotechnology: Pharmaceutical Preparations
  • GLDG Precious Metals
  • Sector
  • PBYI Health Care
  • GLDG Basic Materials
  • Exchange
  • PBYI Nasdaq
  • GLDG Nasdaq
  • Market Cap
  • PBYI 164.3M
  • GLDG 152.8M
  • IPO Year
  • PBYI N/A
  • GLDG N/A
  • Fundamental
  • Price
  • PBYI $3.54
  • GLDG $0.73
  • Analyst Decision
  • PBYI Strong Buy
  • GLDG Strong Buy
  • Analyst Count
  • PBYI 1
  • GLDG 1
  • Target Price
  • PBYI $7.00
  • GLDG $3.25
  • AVG Volume (30 Days)
  • PBYI 306.9K
  • GLDG 607.7K
  • Earning Date
  • PBYI 07-31-2025
  • GLDG 07-15-2025
  • Dividend Yield
  • PBYI N/A
  • GLDG N/A
  • EPS Growth
  • PBYI 143.51
  • GLDG N/A
  • EPS
  • PBYI 0.77
  • GLDG N/A
  • Revenue
  • PBYI $232,709,000.00
  • GLDG N/A
  • Revenue This Year
  • PBYI N/A
  • GLDG N/A
  • Revenue Next Year
  • PBYI N/A
  • GLDG N/A
  • P/E Ratio
  • PBYI $4.64
  • GLDG N/A
  • Revenue Growth
  • PBYI 2.68
  • GLDG N/A
  • 52 Week Low
  • PBYI $2.23
  • GLDG $0.71
  • 52 Week High
  • PBYI $4.13
  • GLDG $1.06
  • Technical
  • Relative Strength Index (RSI)
  • PBYI 58.61
  • GLDG 43.16
  • Support Level
  • PBYI $3.26
  • GLDG $0.73
  • Resistance Level
  • PBYI $3.65
  • GLDG $0.78
  • Average True Range (ATR)
  • PBYI 0.14
  • GLDG 0.02
  • MACD
  • PBYI 0.01
  • GLDG -0.00
  • Stochastic Oscillator
  • PBYI 84.78
  • GLDG 13.33

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

About GLDG GoldMining Inc.

GoldMining Inc is a mineral exploration company with a focus on the acquisition, exploration, and development of projects in Colombia, Brazil, the United States, Canada, and Peru. The principal projects are its La Mina Gold project and its Titiribi Gold-Copper project, located in Colombia; Crucero project, located in Peru; Sao Jorge, Batistao, located in Brazil; Yellowknife Gold Project, located in the Northwest Territories, Canada; and various other projects such as Cachoeira, Yarumalito, Whistler, Surubim, Montes Aureos and Trinta, Rea across different locations. The company has two operating segments, with U.S. GoldMining being one distinct operating segment and all other subsidiaries, or Others, being the second operating segment.

Share on Social Networks: